Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | PREP | P48147 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564603 | 1.00 | CHRM1 (0.66) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL21739046 | 1.00 | CHRM1 (0.66) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL24700254 | 0.98 | CHRM1 (0.64) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL25890368 | 0.88 | CHRM1 (0.62) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL30534558 | 0.88 | CHRM1 (0.62) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL18235300 | 0.86 | CHRM1 (0.60) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL4479232 | 0.85 | CHRM2 (0.59) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL22341040 | 0.84 | CHRM2 (0.71) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL26251587 | 0.84 | CHRM2 (0.71) | CHRM1CHRM2CHRM3PREPHPGD | |
| SCHEMBL24700394 | 0.83 | CHRM2 (0.47) | CHRM1CHRM2CHRM3PREPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | CHRM1 1507/4885CHRM2 1570/4885CHRM3 1618/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | CHRM1 1677/4885CHRM2 1738/4885CHRM3 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.